CJ-1639: A potent and highly selective dopamine D3 receptor full agonist

ACS Medicinal Chemistry Letters

Volumn 2, Issue 8, 2011, Pages 620-625

  Chen, Jianyong ^a   Collins, Gregory T ^a   Levant, Beth ^c   Woods, James ^a   Deschamps, Jeffrey R ^d   Wang, Shaomeng ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^d NAVAL RESEARCH LABORATORY   (United States)

Author keywords

agonists; Dopamine receptors; drug abuse; ligands

Indexed keywords

BP 897; CJ 1037; CJ 1598; CJ 1600; CJ 1638; CJ 1639; CJ 998; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 3 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR STIMULATING AGENT; L 741 626; N [4 [2 (6 CYANO 1,2,3,4 TETRAHYDRO 2 ISOQUINOLINYL)ETHYL]CYCLOHEXYL] 4 QUINOLINECARBOXAMIDE; NGB 2904; PRAMIPEXOLE; QUINPIROLE; RPG 648; SB 414796; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONCENTRATION RESPONSE; DRUG ACTIVITY; DRUG INHIBITION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; NONHUMAN; PRIORITY JOURNAL; YAWNING;

RATTUS;

EID: 80051726300     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml200100t     Document Type: Article

References (20)

1. Joyce, J. N. Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs Pharmacol. Ther. 2001, 90, 231-259 (Pubitemid 32913478)
2. Crocg, M. A.; Mant, R.; Asherson, P.; Williams, J.; Hode, Y.; Shimohama, S.; Sawada, H.; Kitamura, Y.; Taniguchi, T. Disease model: Parkinson's disease Trends Mol. Med. 2003, 9, 360-365 (Pubitemid 37040032)
3. Volkow, N. D.; Fowler, J. S.; Wang, G. J. Role of dopamine in drug reinforcement and addiction in humans: Results from imaging studies Behav. Pharmacol. 2002, 13, 355-366 (Pubitemid 35178832)
4. Levant, B. The D3 dopamine receptor: Neurobiology and potential clinical relevance Pharmacol. Rev. 1997, 49, 231-252 (Pubitemid 27414914)
5. Newman, A. H.; Grundt, P.; Nader, M. A. Dopamine D3 receptor partial agonists and antagonists as potential drug abuse therapeutic agents J. Med. Chem. 2005, 48, 3663-3679 (Pubitemid 40776839)
6. Heidbreder, C. A.; Newman, A. H. Current perspectives on selective dopamine D(3) receptor antagonists as pharmacotherapeutics for addictions and related disorders Ann. N.Y. Acad. Sci. 2010, 1187, 4-34
7. Collins, G. T.; Newman, A. H.; Grundt, P.; Rice, K. C.; Husbands, S. M.; Chauvignac, C.; Chen, J.; Wang, S.; Woods, J. H. Yawning and hypothermia in rats: Effects of dopamine D3 and D2 agonists and antagonists Psychopharmacology (Berlin) 2007, 193, 159-170 (Pubitemid 47025018)
8. Collins, G. T.; Witkin, J. M.; Newman, A. H.; Svensson, K. A.; Grundt, P.; Cao, J.; Woods, J. H. Dopamine Agonist-Induced Yawning in Rats: A Dopamine D3 Receptor-Mediated Behavior J. Pharmacol. Exp. Ther. 2005, 314, 310-319 (Pubitemid 41058268)
9. Reavill, C.; Taylor, S. G.; Wood, M. D.; Ashmeade, T.; Austin, N. E.; Avenell, K. Y.; Boyfield, I.; Branch, C. L.; Cilia, J.; Coldwell, M. C. Pharmacological actions of a novel, high-affinity, and selective human dopamine D3 receptor antagonist, SB-277011-A J. Pharmacol. Exp. Ther. 2000, 294, 1154-1165 (Pubitemid 30666872)
10. Macdonald, G. J.; Branch, C. L.; Hadley, M. S.; Johnson, C. N.; Nash, D. J.; Smith, A. B.; Stemp, G.; Thewlis, K. M.; Vong, A. K.; Austin, N. E.; Jeffrey, P.; Winborn, K. Y.; Boyfield, I.; Hagan, J. J.; Middlemiss, D. N.; Reavill, C.; Riley, G. J.; Watson, J. M.; Wood, M.; Parker, S. G.; Ashby, C. R. Design and synthesis of trans-3-(2-(4-((3-(3-(5-methyl-1,2,4-oxadiazolyl))- phenyl)carboxamido)cyclohexyl)ethyl)-7-methylsulfonyl-2,3,4,5-tetrahydro-1H-3- benzazepine (SB-414796): A potent and selective dopamine D3 receptor antagonist J. Med. Chem. 2003, 46, 4952-4964 (Pubitemid 37355955)
11. Yuan, J.; Chen, X.; Brodbeck, R.; Primus, R.; Braun, J.; Wasley, J. W. F.; Thurkauf, A. NGB 2904 and NGB 2849: Two highly selective dopamine D3 receptor antagonists Bioorg. Med. Chem. Lett. 1998, 8, 2715-2718 (Pubitemid 28496658)
12. Pilla, M; Perachon, S; Sautel, F; Garrido, F; Mann, A; Wermuth, C. G.; Schwartz, J. C.; Everitt, B. J.; Sokoloff, P. Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist Nature 1999, 400, 371-375 (Pubitemid 29344203)
13. Newman, A. H.; Grundt, P.; Cyriac, G.; Deschamps, J. R.; Taylor, M.; Kumar, R.; Ho, D.; Luedtke, R. R. N-(4-(4-(2,3-Dichloro- or 2-methoxyphenyl) piperazin-1-yl)butyl)heterobiarylcarboxamides with Functionalized Linking Chains as High Affinity and Enantioselective D3 Receptor Antagonists J. Med. Chem. 2009, 52, 2559-2570
14. Micheli, F.; Arista, L.; Bonanomi, G.; Blaney, F. E.; Braggio, S.; Capelli, A. M.; Checchia, A.; Damiani, F.; Di-Fabio, R.; Fontana, S.; Gentile, G.; Griffante, C.; Hamprecht, D.; Marchioro, C.; Mugnaini, M.; Piner, J.; Ratti, E.; Tedesco, G.; Tarsi, L.; Terreni, S.; Worby, A.; Ashby, C. R.; Heidbreder, C. 1,2,4-Triazolyl azabicyclo[3.1.0]hexanes: A new series of potent and selective dopamine D(3) receptor antagonists J. Med. Chem. 2010, 53, 374-391
15. Chen, J.; Collins, G. T.; Zhang, J.; Yang, C.-Y.; Levant, B.; Woods, J.; Wang, S. Design, synthesis and evaluation of potent and highly selective dopamine 3 receptor ligands with a novel profile of pharmacologic and behavioral activity J. Med. Chem. 2008, 51, 5905-5908
16. Grundt, P.; Prevatt, K. M; Cao, J.; Taylor, M.; Floresca, C. Z.; Choi, J.-K.; Jenkins, B. G.; Luedtke, R. R.; Newman, A. H. Heterocyclic Analogues of N-(4-(4-(2,3-Dichlorophenyl)piperazin-1-yl)butyl)arylcarboxamides with Functionalized Linking Chains as Novel Dopamine D3 Receptor Ligands: Potential Substance Abuse Therapeutic Agents J. Med. Chem. 2007, 50, 4135-4146 (Pubitemid 47301745)
17. Collins, G. T.; Calinski, D. M.; Newman, A. H.; Grundt, P.; Woods, J. H. Food restriction alters N′-propyl-4,5,6,7-tetrahydrobenzothiazole-2,6- diamine dihydrochloride (pramipexole)-induced yawning, hypothermia, and locomotor activity in rats: Evidence for sensitization of dopamine D2 receptor-mediated effects J. Pharmacol. Exp. Ther. 2008, 325, 691-697 (Pubitemid 351574782)
18. Boulay, D.; Depoortere, R.; Perrault, G.; Borrelli, E.; Sanger, D. J. Dopamine D2 receptor knock-out mice are insensitive to the hypolocomotor and hypothermic effects of dopamine D2/D3 receptor agonists Neuropharmacology 1999, 38, 1389-1396 (Pubitemid 29333155)
19. Chaperon, F.; Tricklebank, M. D.; Unger, L.; Neijt, H. C. Evidence for regulation of body temperature in rats by dopamine D2 receptor and possible influence of D1 but not D3 and D4 receptors Neuropharmacology 2003, 44, 1047-1053 (Pubitemid 36570429)
20. Kulagowski, J. J.; Broughton, H. B.; Curtis, N. R.; Mawer, I. M.; Ridgill, M. P.; Baker, R.; Emms, F.; Freedman, S. B.; Marwood, R.; Patel, S.; Ragan, C. I.; Leeson, P. D. 3-[[4-(4-Chlorophenyl)piperazin-1-yl]methyl]-1H- pyrrolo[2,3-b]pyridine: An Antagonist with High Affinity and Selectivity for the Human Dopamine D4 Receptor J. Med. Chem. 1996, 39, 1941-1942 (Pubitemid 26163243)